284 related articles for article (PubMed ID: 20053331)
1. Hepatic safety of voriconazole after allogeneic hematopoietic stem cell transplantation.
Amigues I; Cohen N; Chung D; Seo SK; Plescia C; Jakubowski A; Barker J; Papanicolaou GA
Biol Blood Marrow Transplant; 2010 Jan; 16(1):46-52. PubMed ID: 20053331
[TBL] [Abstract][Full Text] [Related]
2. Reasons for voriconazole prophylaxis discontinuation in allogeneic hematopoietic cell transplant recipients: A real-life paradigm.
Chan SY; Hughes RM; Woo K; Perales MA; Neofytos D; Papanicolaou G
Med Mycol; 2020 Nov; 58(8):1029-1036. PubMed ID: 32171012
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of hepatotoxicity with off-label oral-treatment doses of voriconazole for invasive fungal infections.
Gorski E; Esterly JS; Postelnick M; Trifilio S; Fotis M; Scheetz MH
Antimicrob Agents Chemother; 2011 Jan; 55(1):184-9. PubMed ID: 20974867
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole versus fluconazole in allogeneic blood hematopoietic stem cell transplantation recipients-A retrospective analysis of a single medical center in Taiwan.
Wang CH; Kan LP; Lin HA; Chang FY; Wang NC; Lin TY; Chao TY; Kao WY; Ho CL; Chen YC; Dai MS; Chang PY; Wu YY; Lin JC
J Microbiol Immunol Infect; 2016 Aug; 49(4):531-8. PubMed ID: 25440977
[TBL] [Abstract][Full Text] [Related]
5. Voriconazole hepatotoxicity in severe liver dysfunction.
Solís-Muñoz P; López JC; Bernal W; Willars C; Verma A; Heneghan MA; Wendon J; Auzinger G
J Infect; 2013 Jan; 66(1):80-6. PubMed ID: 23041040
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for voriconazole hepatotoxicity at 12 weeks in lung transplant recipients.
Luong ML; Hosseini-Moghaddam SM; Singer LG; Chaparro C; Azad S; Lazar N; Boutros PC; Keshavjee S; Rotstein C; Husain S
Am J Transplant; 2012 Jul; 12(7):1929-35. PubMed ID: 22486950
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease.
Krishna G; Martinho M; Chandrasekar P; Ullmann AJ; Patino H
Pharmacotherapy; 2007 Dec; 27(12):1627-36. PubMed ID: 18041883
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of isavuconazole compared with voriconazole as primary antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients.
Bogler Y; Stern A; Su Y; Lee YJ; Seo SK; Shaffer B; Perales MA; Papanicolaou GA; Neofytos D
Med Mycol; 2021 Oct; 59(10):970-979. PubMed ID: 34036319
[TBL] [Abstract][Full Text] [Related]
9. Incidence of voriconazole hepatotoxicity during intravenous and oral treatment for invasive fungal infections.
den Hollander JG; van Arkel C; Rijnders BJ; Lugtenburg PJ; de Marie S; Levin MD
J Antimicrob Chemother; 2006 Jun; 57(6):1248-50. PubMed ID: 16556632
[TBL] [Abstract][Full Text] [Related]
10. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients.
Trifilio S; Ortiz R; Pennick G; Verma A; Pi J; Stosor V; Zembower T; Mehta J
Bone Marrow Transplant; 2005 Mar; 35(5):509-13. PubMed ID: 15654347
[TBL] [Abstract][Full Text] [Related]
11. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation.
Marty FM; Lowry CM; Cutler CS; Campbell BJ; Fiumara K; Baden LR; Antin JH
Biol Blood Marrow Transplant; 2006 May; 12(5):552-9. PubMed ID: 16635790
[TBL] [Abstract][Full Text] [Related]
12. Voriconazole-induced phototoxicity masquerading as chronic graft-versus-host disease of the skin in allogeneic hematopoietic cell transplant recipients.
Patel AR; Turner ML; Baird K; Gea-Banacloche J; Mitchell S; Pavletic SZ; Wise B; Cowen EW
Biol Blood Marrow Transplant; 2009 Mar; 15(3):370-6. PubMed ID: 19203729
[TBL] [Abstract][Full Text] [Related]
13. Management of voriconazole hepatotoxicity in a lung transplant patient.
Belaiche S; Roustit M; Bedouch P; Quetant S; Saint-Raymond C; Pison C
Transpl Infect Dis; 2011 Jun; 13(3):309-11. PubMed ID: 21176020
[TBL] [Abstract][Full Text] [Related]
14. Drug interaction between voriconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplant recipients.
Mori T; Aisa Y; Kato J; Nakamura Y; Ikeda Y; Okamoto S
Bone Marrow Transplant; 2009 Sep; 44(6):371-4. PubMed ID: 19270729
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and safety of 14 days intravenous voriconazole in allogeneic haematopoietic stem cell transplant recipients.
Brüggemann RJ; Blijlevens NM; Burger DM; Franke B; Troke PF; Donnelly JP
J Antimicrob Chemother; 2010 Jan; 65(1):107-13. PubMed ID: 19933691
[TBL] [Abstract][Full Text] [Related]
16. Risk factors associated with liver injury and impact of liver injury on transplantation-related mortality in pediatric recipients of allogeneic hematopoietic stem cell transplantation.
Radhakrishnan K; Bishop J; Jin Z; Kothari K; Bhatia M; George D; Garvin JH; Martinez M; Ovchinsky N; Lobritto S; Elsayed Y; Satwani P
Biol Blood Marrow Transplant; 2013 Jun; 19(6):912-7. PubMed ID: 23467127
[TBL] [Abstract][Full Text] [Related]
17. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children.
Walsh TJ; Lutsar I; Driscoll T; Dupont B; Roden M; Ghahramani P; Hodges M; Groll AH; Perfect JR
Pediatr Infect Dis J; 2002 Mar; 21(3):240-8. PubMed ID: 12005089
[TBL] [Abstract][Full Text] [Related]
18. Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events.
Chu HY; Jain R; Xie H; Pottinger P; Fredricks DN
BMC Infect Dis; 2013 Feb; 13():105. PubMed ID: 23442261
[TBL] [Abstract][Full Text] [Related]
19. Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation.
Marks DI; Pagliuca A; Kibbler CC; Glasmacher A; Heussel CP; Kantecki M; Miller PJ; Ribaud P; Schlamm HT; Solano C; Cook G;
Br J Haematol; 2011 Nov; 155(3):318-27. PubMed ID: 21880032
[TBL] [Abstract][Full Text] [Related]
20. Experience with anidulafungin in patients with allogeneic hematopoietic stem cell transplantation and graft-versus-host disease.
Yáñez L; Insunza A; Ibarrondo P; de Miguel C; Bermúdez A; Colorado M; López-Duarte M; Richard C; Conde E
Transpl Infect Dis; 2015 Oct; 17(5):761-7. PubMed ID: 26250790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]